Biota Holdings targeting asthma market with flu drug – Australian Life Scientist

Biota Holdings targeting asthma market with flu drug
Australian Life Scientist
Biota Holdingstoday commenced a 400-member trial in the US of its anti-viral drug BTA798 on sufferers of asthma who have contracted cold and flu.
HRV Phase II Trial Underway in PatientsPharmaLive (press release) (subscription)

all 2 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *